Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10441630 | SUN PHARM | Topical formulations and uses thereof |
Aug, 2033
(10 years from now) | |
US8980839 | SUN PHARM | Topical aqueous nanomicellar, ophthalmic solutions and uses thereof |
Aug, 2033
(10 years from now) | |
US9937225 | SUN PHARM | Topical formulations and uses thereof |
Aug, 2033
(10 years from now) | |
US10918694 | SUN PHARM | Topical cyclosporine-containing formulations and uses thereof |
Feb, 2037
(14 years from now) |
Market Authorisation Date: 14 August, 2018
Treatment: Increase tear production in patients with keratoconjunctivitis sicca (dry eye).
Dosage: SOLUTION;OPHTHALMIC
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8648048 | ALLERGAN | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(1 year, 6 months from now) | |
US8633162 | ALLERGAN | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(1 year, 6 months from now) | |
US9248191 | ALLERGAN | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(1 year, 6 months from now) | |
US8685930 | ALLERGAN | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(1 year, 6 months from now) | |
US8629111 | ALLERGAN | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(1 year, 6 months from now) | |
US8642556 | ALLERGAN | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(1 year, 6 months from now) | |
US8292129 | ALLERGAN | Dispensing device |
Feb, 2031
(8 years from now) | |
US8561859 | ALLERGAN | Dispensing device |
Apr, 2032
(9 years from now) | |
US9676525 | ALLERGAN | Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids |
Feb, 2034
(11 years from now) | |
US9669974 | ALLERGAN | Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids |
May, 2034
(11 years from now) |
Market Authorisation Date: 23 December, 2002
Treatment: Increase tear production in patients with keratoconjunctivitis sicca (dry eye).; Increase tear production to treat patients with keratoconjunctivitis sicca (dry eye).
Dosage: EMULSION;OPHTHALMIC
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7973081 | SANTEN | Emulsion compositions containing quaternary ammonium compounds |
Jan, 2026
(2 years from now) | |
US9956289 | SANTEN | Emulsion compositions containing quaternary ammonium compounds |
Jan, 2026
(2 years from now) | |
US8524779 | SANTEN | Emulsion compositions containing quaternary ammonium compounds |
Jan, 2026
(2 years from now) | |
US9220694 | SANTEN | Emulsion compositions containing cetalkonium chloride |
Jan, 2026
(2 years from now) | |
US8298568 | SANTEN | Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential |
Nov, 2027
(4 years from now) | |
US9132071 | SANTEN | Compositions containing quaternary ammonium compounds |
Jun, 2029
(6 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Jun 23, 2028 |
New Product (NP) | Jun 23, 2023 |
Market Authorisation Date: 23 June, 2021
Treatment: NA
Dosage: EMULSION;OPHTHALMIC
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic